Quick Answer
FILANA THERAPEUTICS, INC. reported Net Income Loss of -$90.97 million for the year ending 2025.
- FILANA THERAPEUTICS, INC. showed a decrease of -273.7% in Net Income Loss from 2024 to 2025.
- This data is from FILANA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$3.45 million | Q2 2014: -$3.25 million | Q3 2014: -$3.53 million | Q4 2014: -$2.16 million | Q1 2015: -$2.58 million | Q2 2015: -$3.37 million | Q3 2015: -$3.67 million | Q4 2015: -$4.52 million | Q1 2016: -$5.80 million | Q2 2016: -$3.02 million | Q3 2016: -$3.52 million | Q4 2016: -$2.52 million | Q1 2017: -$2.74 million | Q2 2017: -$4.16 million | Q3 2017: -$2.59 million | Q1 2018: -$2.16 million | Q2 2018: -$2.45 million | Q3 2018: -$1.27 million | Q1 2019: -$1.36 million | Q2 2019: -$1.06 million | Q3 2019: -$697.0 thousand | Q1 2020: -$1.15 million | Q2 2020: -$1.14 million | Q3 2020: -$1.43 million | Q1 2021: -$3.53 million | Q2 2021: -$5.13 million | Q3 2021: -$9.56 million | Q1 2022: -$17.53 million | Q2 2022: -$19.33 million | Q3 2022: -$20.26 million | Q1 2023: -$24.27 million | Q2 2023: -$26.38 million | Q3 2023: -$25.65 million | Q1 2024: $25.04 million | Q2 2024: $6.16 million | Q3 2024: -$27.94 million | Q1 2025: -$23.40 million | Q2 2025: -$44.22 million | Q3 2025: -$10.81 million.
- Over the full 17 years of available data (2009 to 2025), FILANA THERAPEUTICS, INC.'s Net Income Loss has declined by 2,524.0%.
- Historical annual values: Fiscal year 2025: -$90.97 million | Fiscal year 2024: -$24.34 million | Fiscal year 2023: -$97.22 million | Fiscal year 2022: -$76.25 million | Fiscal year 2021: -$32.39 million | Fiscal year 2020: -$6.33 million | Fiscal year 2019: -$4.63 million | Fiscal year 2018: -$6.56 million | Fiscal year 2017: -$11.91 million | Fiscal year 2016: -$14.85 million | Fiscal year 2015: -$14.15 million | Fiscal year 2014: -$12.39 million | Fiscal year 2013: $31.54 million | Fiscal year 2012: -$3.45 million | Fiscal year 2011: -$2.61 million | Fiscal year 2010: -$12.02 million | Fiscal year 2009: -$3.47 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: